Skip to content

A clinical study on effect of EGC of cold-brew tea on immune function -a randomized, placebo controlled, double blind, parallel-group comparison clinical test-

A clinical study on effect of EGC of cold-brew tea on immune function -a randomized, placebo controlled, double blind, parallel-group comparison clinical test- - A clinical study on effect of EGC of cold-brew tea on immune function -a randomized, placebo controlled, double blind, parallel-group comparison clinical test-

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000049031
Enrollment
40
Registered
2022-09-28
Start date
2022-09-29
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

The test food tea bag is brewed with water in a 400 mL bottle and drink it as a daily dose for 4 weeks. The placebo food tea bag is brewed with water in a 400 mL bottle and drink it as a daily dose fo

Sponsors

Graduate School of Medical Science, Kyoto Prefectural University of Medicine Department of Human Immunology and Nutrition Science
Lead Sponsor
National Agriculture and Food Research Organization Institute of Fruit Tree and Tea Science
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged between 50 and less than 75 years old. 2. Japanese males and females 3. Those who can input their own data into the electronic diary. 4. Those who received sufficient explanation for the objective and summary of the trial, and voluntarily volunteered to the trial with the agreement of informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who are receiving any types of medicines and/or Chinese medical treatment except a dose of medicine taken only once. 2. Those who have medical treatments such a diet therapy and/or an exercise therapy. 3. Those who had been experiencing a severe disease. 4. Those who currently have or have history of allergic dermatitis, allergic rhinitis, bronchial asthma, and chronic bronchitis. 5. Those who have currently been taking commercially available drugs, quasi-drug products, and foods or supplements with functional claims. However, those who can discontinue taking these foods during the trial period after obtaining informed consent will be allowed to join the trial. 6. Those who have currently been taking yogurts, Lactobacillus or Bifidobacterium containing foods or beverage. In the case of beverage type or solid type, it is applicable if it is 50g/day or more. In the case of tablet or capsule type, it is applicable if it is ingested more than once specified by the sales company. 7. Those who have currently been taking cold-brew tea. 8. Those who have a drug/food allergy. 9. Those who drink more than 60 g alcohol/day. 10. Those who have excessive smoking habits (21 or more cigarettes / day). 11. Those who work on night shift jobs and the shiftwork. 12. Those who have plans of major change on their lifestyle (e.g. diet, sleep and exercise) during the study period. 13. Those who are planning to travel abroad during the study period. 14. Those who have joined other clinical trials in the past 1 month before receiving informed consent in this study, or are currently joining other clinical trials, or are planning to join other clinical trials. 15. Those who are unsuitable for this trial that judged by the principal investigator.

Design outcomes

Primary

MeasureTime frame
Questionnaire for physical condition and stress

Secondary

MeasureTime frame
Blood immune index Immune cell profiling Immune index of saliva Oral flora Intestinal flora Body temperature

Countries

Japan

Contacts

Public ContactHirokuni Kayama

IMEQRD Co., Ltd Planning and Sales Department

clinical-trial@imeqrd.co.jp03-6704-5968

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026